Trial Profile
A phase II study of OSI-774 (Tarceva) [erlotinib] in combination with oxaliplatin and capecitabine in previously treated patients with stage IV colorectal cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2009
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 01 Nov 2005 New trial record.